Trichomoniasis
Also known as: Trich
Methodology & AI Transparency ⓘ
Trichomoniasis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Trichomoniasis is a sexually transmitted infection (STI) caused by a parasite.
- 2 Real-world patient consensus: Mapped to Weight Management & Metabolic Syndrome under ICD-10-CM E66.3 for Trichomoniasis clinical workups.
- 3 Typical cash cost range: Clinicians assessing Trichomoniasis focus on hypothalamic arcuate nucleus in Trichomoniasis (E66.3: leptin resistance) and targeted history.
- 4 Top reported side effects / signs: Key Weight & Metabolism biomarkers for Trichomoniasis (E66.3): ALT & Fasting in Trichomoniasis (E66.3: Triglycerides) & DEXA Visceral Adipose in Trichomoniasis (E66.3: Tissue (VAT)) (< 1.0 lb (< 100 cm2) (E66.3)).
Ask our AI Specialists anything about Trichomoniasis
What Is Trichomoniasis?
Trichomoniasis is a sexually transmitted infection (STI) caused by a parasite. It spreads from person to person during sex. Many people do not have any symptoms. If you do get symptoms, they usually happen within 5 to 28 days after being infected. It can cause vaginitis in women. Symptoms include: Yellow-green or gray discharge from the vagina Discomfort during sex Vaginal odor Painful urination Itching burning, and soreness of the vagina and vulva Most men do not have symptoms.
Pathophysiology, Underlying Causes & Clinical Presentation
Trichomoniasis (E66.3) alters weight & metabolism homeostasis through hypothalamic arcuate nucleus in Trichomoniasis (E66.3: leptin resistance); Cross-referenced with NIH MeSH (Trichomonas Vaginitis), clinical remission targets DEXA Visceral Adipose in Trichomoniasis (E66.3: Tissue (VAT)) within < 1.0 lb (< 100 cm2) (E66.3).
Common Symptoms & Clinical Signs
- • Yellow-green or gray discharge from the vagina
- • Discomfort during sex
- • Presentation of Trichomoniasis (E66.3): persistent hunger signaling [Trichomoniasis E66.3]
- • Secondary Trichomoniasis clinical sign: co-existing blood pressure, in Trichomoniasis (E66.3: triglyceride, or fasting)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Trichomoniasis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E66.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Weight Management & Metabolic Syndrome | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: ALT & Fasting in Trichomoniasis (E66.3: Triglycerides) | ALT < 25 U/L; TG < 100 mg/dL (E66.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: DEXA Visceral Adipose in Trichomoniasis (E66.3: Tissue (VAT)) | < 1.0 lb (< 100 cm2) (E66.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Waist-to-Height Ratio [Trichomoniasis E66.3] | < 0.50 (E66.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Trichomoniasis
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Tinidazole Tindazole, Tindamax • RxCUI 199519 | Nitroimidazole Antimicrobial | 77% | $1.2526 | $ 50.38 /mo |
| Likmez (Metronidazole Oral) Likmez • RxCUI 2667648 | Nitroimidazole Antimicrobial | 92% | $2.5938 | $ 195.25 /mo |
| Metronidazole Noritate, Vagizole • RxCUI 311681 | Nitroimidazole Antimicrobial | 88% | $0.0999 | $ 6.08 /mo |
| Metronidazole Oral Likmez, Flagyl • RxCUI 2667642 | Nitroimidazole Antimicrobial | 90% | $2.5938 | $ 6.08 /mo |
| Tindazole (Tinidazole) Tindazole • RxCUI 199519-B705184172 | Nitroimidazole Antimicrobial | 74% | $1.2526 | $ 98.68 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Trichomoniasis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| What the Latest Evidence Really Says About Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing In this NMA, tirzepatide appeared to be superior to semaglutide in both body weight reduction and improvement of glycemic indices. Journal of diabetes • 2026-02-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 41664890 ↗ |
| Can This Approach Help? Inside the Latest Research on Characterization of the effect of naltrexone/bupropion on body NB-induced weight loss is associated with significant reductions in total percent fat mass, increase in total percent lean mass, and change in lean-to-fat mass ratio, in comparison to placebo. Diabetes, obesity & metabolism • 2025-05-15 • Phase III Randomized Trial | N = 82 | 88/100 | PMID 39927409 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of single-dose oral secnidazole for the treatment of trichomoniasis in Single-dose oral secnidazole 2 g was highly efficacious in curing trichomoniasis in women co-infected with BV. BMJ open • 2023-08-07 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37550019 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Single Oral Dosing of Secnidazole for Trichomoniasis in A single oral 2 g dose of secnidazole was associated with significantly higher microbiological cure rates vs placebo, supporting a role for secnidazole in treating women with trichomoniasis, including those with HIV and/or BV. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2021-09-15 • Phase III Randomized Trial | N = 100 | 88/100 | PMID 33768237 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of semaglutide versus placebo for people with schizophrenia Semaglutide led to significantly greater weight loss than placebo in this small trial without affecting psychotic symptoms or clozapine concentrations. The lancet. Psychiatry • 2025-07-15 • Randomized Controlled Trial | N = 15 | 88/100 | PMID 40506208 ↗ |
Trichomoniasis Patient Community & “People Like Me” Threads
Filter Trichomoniasis community threads and patient logs by age, biological sex, dosage, and treatment duration.